Pfizer Inc.'s acquisition of Hospira could signal that investors should embrace biosimilar drugmakers.
Three drug companies to watch as biologics come off patent and investors anticipate a biosimilar boom -- here's what you need to know.
Gilead Sciences has fallen by double-digits from its 52-week high. Is the stock now too cheap to ignore?
Pfizer recently acquired Hospira for $17 billion, but it has plenty of fuel left to go after more deals to boost its pipeline and shareholder value.
Motley Fool experts offer up insight into three intriguing small-cap biotech stocks.
Exciting but speculative -- Industry Focus examines two companies making strides in the treatment of hepatitis C.
Biogen Idec, Regeneron, and Amgen Inc. may be better bets than Gilead Sciences.
Pfizer's management has been slowly steering the company toward a game-changing split. Will this much anticipated event finally take place in 2015?
Shares of this clinical-stage biotech are crashing today. Here's why.
Multiple sclerosis affects more than 400,000 people in the United States and around 2.5 million people globally. That's why this potentially game-changing study's results are so promising and important.